Galapagos (NASDAQ:GLPG) Trading Up 3.7%

Galapagos NV (NASDAQ:GLPG)’s stock price shot up 3.7% on Tuesday . The stock traded as high as $29.54 and last traded at $29.43. 132,275 shares were traded during mid-day trading, an increase of 2% from the average session volume of 129,142 shares. The stock had previously closed at $28.39.

Wall Street Analyst Weigh In

Separately, Raymond James lowered Galapagos from an “outperform” rating to a “market perform” rating in a research report on Friday, August 2nd.

Galapagos Price Performance

The firm’s 50-day simple moving average is $25.88 and its 200 day simple moving average is $29.50.

Institutional Investors Weigh In On Galapagos

A number of hedge funds have recently modified their holdings of the stock. Headlands Technologies LLC raised its stake in shares of Galapagos by 949.3% in the first quarter. Headlands Technologies LLC now owns 787 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 712 shares during the period. GAMMA Investing LLC bought a new stake in Galapagos in the fourth quarter worth $44,000. Quadrant Capital Group LLC boosted its position in Galapagos by 18.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 261 shares during the period. Signaturefd LLC grew its stake in shares of Galapagos by 78.6% during the fourth quarter. Signaturefd LLC now owns 1,970 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 867 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Galapagos by 21.6% in the 2nd quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 814 shares during the last quarter. Institutional investors own 32.46% of the company’s stock.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.